Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Nature Communications|October 25, 2024
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I Silverberg, David Rosmarin, Raj Chovatiya, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 23, 2021
Passivation of the Buried Interface via Preferential Crystallization of 2D Perovskite on Metal Oxide Transport LayersBin Chen, Hao Chen, Yi Hou, et al.
Light, Science & Applications|March 3, 2023
In-situ growth of low-dimensional perovskite-based insular nanocrystals for highly efficient light emitting diodesHao Wang, Weidong Xu, Qi Wei, et al.
European Urology|June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.
Nature Communications|April 24, 2026
Uniform and ordered self-assembled hole-selective layers driven by π-π interactions for efficient perovskite-silicon tandem solar cellsMing Luo, Zhou Liu, Qi Huang, et al.
Journal for Immunotherapy of Cancer|April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M Tannir, Daniel C Cho, Adi Diab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2021
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 AntibodyJames J Harding, Victor Moreno, Yung-Jue Bang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
National Science Review|April 5, 2024
Surface heterojunction based on n-type low-dimensional perovskite film for highly efficient perovskite tandem solar cellsXianyuan Jiang, Qilin Zhou, Yue Lu, et al.
Pageof 6